Data Collection

Question 1

How many patients was in the Cefdinir project

Answer 1

230 patients were included in the final study analysis with 113 in the cefdinir group and 117 in the other oral cephalosporin
group

Question 2

Cefdinir primary outcome

Answer 2

Evaluate rates UTI recurrence with the same organism within 30 days of completing IV antibiotics followed by cefdinir

Question 3

Cefdinir secondary outcome

Answer 3

Recurrent UTI with any organism within 30 days

Question 4

Cefdinir result

Answer 4

This study found no difference in incidence of UTI recurrence after treatment with cefdinir compared to other oral cephalosporins.

Question 5

Standard enoxaparin VTE
prophylaxis

Answer 5

40 mg SQ daily

Question 6

Standard heparin VTE
prophylaxis

Answer 6

5000 units SQ q8h

Question 7

Intermediate enoxaparin VTE prophylaxis

Answer 7

0.5 mg/kg SQ twice daily

Question 8

Intermediate heparin VTE prophylaxis

Answer 8

7500 units SQ q8h

Question 9

enoxaparin VTE treatment

Answer 9

1 mg/kg SQ twice daily

Question 10

heparin VTE treatment

Answer 10

drip

Question 11

when to use Standard VTE
prophylaxis

Answer 11

D-dimer < 3 mcg/mL

Question 12

when to use Intermediate VTE
prophylaxis

Answer 12

D-dimer >3 mcg/mL
or ICU admission

Question 13

Devyn primary outcome

Answer 13

Incidence of thromboembolism when Mount Carmel COVID Treatment Guideline is appropriately utilized to initiate anticoagulation

Incidence of thromboembolism with standard, intermediate, and therapeutic anticoagulation

Question 14

Devyn results

Answer 14

There were no statistically significant differences in dosing intensity of anticoagulants for
prevention of VTE formation when comparing standard, intermediate, and therapeutic dosing
regimens.

Question 15

How many patient in devyn’s project

Answer 15

482 patients were included in this study. Enoxaparin was prescribed on admission for 290 patients, heparin was prescribed for 127 patients, and a DOAC was prescribed for 65
patients.

Question 16

HF primary outcome

Answer 16

rate of GDMT
optimization based on various factors.

Question 17

HF number of patients

Answer 17

442 patients met criteria for this study.

Question 18

HF results

Answer 18

284 (64.25%) received some form of GDMT optimization, the majority of which 246 (55.7%) had at least one GDMT drug added.

Patients with cardiology consult were more likely to have GDMT optimization while increased serum creatinine (SCr) and age were associated with a lower chance of GDMT optimization

Question 19

Dificid primary outcome

Answer 19

assess physician adherence to current MCHS fidaxomicin restrictions for CDI, which limit its use to patients with vancomycin failure or those continuing home therapy

Question 20

Dificid secondary outcome

Answer 20

examining proposed updated fidaxomicin restrictions, which allowed its use for patients with recurrent CDI or those at high risk for recurrence/severe CDI

Question 21

Dificid result

Answer 21

35% (17/48) of fidaxomicin patients met the current fidaxomicin restrictions. 92% (44/48) of fidaxomicin treated patients met the proposed restrictions including risk for recurrence.

Question 22

OSU primary outcome

Answer 22

impact of a pharmacy resident antimicrobial stewardship overnight on-call program on clinical outcomes in patients with bloodstream infections (BSI) secondary to multidrug-resistant organisms

Question 23

OSU result

Answer 23

The primary outcome of time from RDT result to first dose administration of optimal antibiotic therapy was a median of 3.3 hours in the PI group versus 2.3 hours in the AI group (p= 0.057). In-hospital mortality, length of stay, and BSI recurrence were similar between groups.